Table 1
Inclusion criteria

Subjects were considered eligible for inclusion if they were 45 years old or older but younger than 70 years old at study entry, had type 2 diabetes and met both “(1) and (2)” or both “(1) and (3)” described below.

(1) Glycemic control: those with HbA1c 6.9% (52 mmol/mol) or greater despite treatment with any of the 3 regimens given below:
   a) diet and exercise therapy alone
   b) diet and exercise therapy plus 1 oral anti-diabetic drug,
   c) diet and exercise therapy plus alpha-GI and another oral anti-diabetic drug

(2) Blood pressure control: those with the following casual BP level as measured on an outpatient basis:
   a) systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg while not taking an antihypertensive drug
   b) systolic BP ≥130 mm Hg or diastolic BP ≥80 mmHg while taking 1 or 2 ARB, ACEI, or long-acting CCB
   Those receiving antihypertensive drugs other than these 3 drugs were not eligible for study entry, with the exception of those who were receiving these drugs for purposes other than blood pressure lowering

(3) Lipid control: those with the following fasting lipid levels not taking a lipid-lowering drug or taking a lipid-lowering drug:
   a) LDL-cholesterol ≥120 mg/dL (as estimated by using the Friedewald formula)
   b) triglycerides ≥150 mg/dL
   c) HDL-cholesterol <40 mg/dL
**Table 2**

Exclusion criteria

1. those with poorly controlled hypertension despite pharmacological therapy 
   (systolic BP ≥200 mm Hg or diastolic BP ≥120 mm Hg)
2. those receiving insulin therapy
3. those with non-diabetic renal disease
4. those in whom type 1 diabetes, due to pathogenic mechanisms other than those associated with type 2 diabetes, is strongly suspected
5. those who tested anti-GAD antibody-positive
6. those with LDL-cholesterol ≥200 mg/dL
7. those suspected of having secondary hypertension other than renal parenchymal hypertension
8. those suspected of having hereditary lipid disorder with a strong family history of lipid metabolic disorder
9. those who were receiving antihypertensive drugs other than ARB, ACEI, or long-acting CCB, except where they were receiving these drugs for purposes other than blood pressure lowering
10. those who were receiving 3 or more antihypertensive drugs (i.e., ARB, ACEI, and long-acting CCB), except where they were receiving these drugs for purposes other than blood pressure lowering
11. those with more serious retinopathy than proliferative retinopathy
12. renal failure (serum Cr: ≥2.0 mg/dL in men; ≥1.5 mg/dL in women)
13. those with a history of cardiac failure or those with cardiac failure
14. those who were pregnant or potentially pregnant
15. those who met any of the following criteria and who had BNP ≥100 pg/mL, myocardial infarction, angina pectoris (or a history of disease), history of coronary artery bypass graft (CABG), history of percutaneous coronary angioplasty (PTCA), other cardiac disease, ECG findings of left ventricular hyperplasia, or abnormal ECG findings (excluding isolated extrasystole or right bundle branch block [RBBB])
16. those judged by the physician in charge to be ineligible for study entry
<table>
<thead>
<tr>
<th></th>
<th>CTG</th>
<th>ITG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight control</td>
<td>Target BMI, ( \leq 24 )</td>
<td>Target BMI, ( \leq 22 )</td>
</tr>
<tr>
<td></td>
<td>Provided with diaries to record their body weight</td>
<td>Provided with diaries to record their body weight</td>
</tr>
<tr>
<td>Diet therapy</td>
<td>Total energy intake, 25-35 kcal/kg according to daily activity; salt intake, ( \leq 6 ) g/day with comorbid hypertension, ( \leq 9 ) g/day in male without hypertension, ( \leq 7.5 ) g/day in female without hypertension (in accordance with the guideline (^{19}))</td>
<td>Total energy intake, ( \leq 25 ) kcal/kg in those with BMI ( \geq 25 ), ( \leq 27 ) kcal/kg in those with BMI ( &lt; 25 ) Lipid intake, ( \leq 25% ) of total energy intake Cholesterol intake, ( \leq 300 ) mg/day Salt intake, ( \leq 6 ) g/day Between-meal and bedtime snacks, prohibited Alcohol (equivalent to 180 mL of sake or less) abstinence to be rigorously adhered to, and obliged to report on alcohol intake Thirty-minute or longer guidance on nutrition by designated national registered dietitians at the start of the study, 1, 3, 6, and 12 months after the start of the study, and every 6 months in the 2nd year afterwards</td>
</tr>
<tr>
<td>Exercise therapy</td>
<td>Two or more 15- to 30-minute walks on a daily basis (in accordance with the guideline (^{19})) Provided with an accelerometer</td>
<td>Two or more 15- to 30-minute walks on a daily basis Provided with an accelerometer, and should report on the calories consumed as well as the number of steps taken every day</td>
</tr>
<tr>
<td>Smoking cessation</td>
<td>Instructed to persevere in their smoking cessation practice and to report at their regular hospital visits on the number of cigarettes smoked Provided with smoking-cessation aids, if necessary</td>
<td></td>
</tr>
<tr>
<td>Education</td>
<td>A core program and a post-core program intended to improve lifestyle habits are to be implemented to ensure lifestyle factors are improved</td>
<td></td>
</tr>
</tbody>
</table>
**Table 4**

Definitions of the events

**Myocardial infarction:**
the presence of typical symptoms (e.g., lasting severe chest pain), echocardiographic changes, abnormal laboratory findings (e.g., elevation of the cardiac enzyme troponin T), or findings of clinical imaging (e.g., coronary angiography, cardiac scintigraphy, multidetector row computed tomography) which were diagnosed as such by a physician.

**Stroke:**
the presence of a newly onset focal symptom lasting more than 24 hours which was diagnosed as such by a physician (preferably with the culprit lesion identified/confirmed on CT or MRI/MRA).

**Occurrence of onset or progression of nephropathy:**
an event when either of the following occurs:

- a. progression from normoalbuminuria (urinary albumin <30 mg/g•Cr) to microalbuminuria (urinary albumin ≥30 mg/g•Cr, <300 mg/g•Cr), or from normoalbuminuria to macroalbuminuria (urinary albumin ≥300 mg/g•Cr)
- b. progression from microalbuminuria to macroalbuminuria
- c. serum creatinine levels elevated 2-fold or more compared to that at study entry
- d. endstage renal failure (permanent dialysis initiated or renal transplant performed)

If a. or b. occurs in a particular subject and the measured urinary albumin value is shown to be 30% higher than that at study entry, the subject is to be re-examined (with a morning urine sample), and if the measured value is 30% higher than that at study entry, this is to be construed as the occurrence of an event.

In the event of c., the subject is also to be re-examined within 3 months of the event.

In a., b., or c., the event is to be evaluated in the first occurrence.

**Occurrence of onset or progression of retinopathy**
an event when either of the following occurs:

- a. progression from absence of retinopathy to nonproliferative retinopathy or proliferative retinopathy
- b. progression from nonproliferative to proliferative retinopathy
- c. loss of vision likely due to retinopathy
### Table 5

Baseline medication

<table>
<thead>
<tr>
<th></th>
<th>CTG (n = 1271)</th>
<th>ITG (n = 1271)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of any antidiabetic (%)</td>
<td>77.2</td>
<td>74.6</td>
<td>0.138</td>
</tr>
<tr>
<td>SU</td>
<td>40.7</td>
<td>40.1</td>
<td>0.808</td>
</tr>
<tr>
<td>Glinides</td>
<td>8.1</td>
<td>7.6</td>
<td>0.658</td>
</tr>
<tr>
<td>BG</td>
<td>14.8</td>
<td>14.2</td>
<td>0.736</td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>6.7</td>
<td>6.5</td>
<td>0.936</td>
</tr>
<tr>
<td>α-GI</td>
<td>28.2</td>
<td>29.0</td>
<td>0.693</td>
</tr>
<tr>
<td>Use of any antihypertensive (%)</td>
<td>40.6</td>
<td>41.7</td>
<td>0.600</td>
</tr>
<tr>
<td>ARB</td>
<td>28.1</td>
<td>28.4</td>
<td>0.895</td>
</tr>
<tr>
<td>ACEI</td>
<td>4.3</td>
<td>5.1</td>
<td>0.400</td>
</tr>
<tr>
<td>Long-acting CCB</td>
<td>23.5</td>
<td>22.4</td>
<td>0.540</td>
</tr>
<tr>
<td>Use of any antilipemic (%)</td>
<td>34.2</td>
<td>32.0</td>
<td>0.255</td>
</tr>
<tr>
<td>Atorvastatin, pitavastatin, or rosvastatin</td>
<td>18.8</td>
<td>17.9</td>
<td>0.609</td>
</tr>
<tr>
<td>Other statins</td>
<td>11.3</td>
<td>9.9</td>
<td>0.274</td>
</tr>
<tr>
<td>Anion-exchange resin</td>
<td>0.0</td>
<td>0.2</td>
<td>0.500</td>
</tr>
<tr>
<td>EPA</td>
<td>1.0</td>
<td>1.3</td>
<td>0.710</td>
</tr>
<tr>
<td>Fibrates</td>
<td>2.8</td>
<td>2.4</td>
<td>0.616</td>
</tr>
</tbody>
</table>

* p values were calculated with the use of Fisher’s exact test.
Figure 1

Funding for J-DOIT3

<table>
<thead>
<tr>
<th>Status</th>
<th>June 2006</th>
<th>March 2009</th>
<th>March 2016 (expected)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accrual period</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up period</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Funding agency</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>JF-PIMRC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>April 2013</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JDF</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Funding by the MHLW</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Strategic Outcomes Research Program for Research on Diabetes and Comprehensive Research on Diabetes/Cardiovascular and Life-Style Related Diseases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>April 2010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health and Labour Sciences Research Grant</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Corporate donations</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
</table>
Multifactorial step-wise treatment in the ITG

**Blood Glucose**

- **Step 0**
  - Category A, if BMI $\geq 25$
  - Category A or B, if BMI 22 to $< 25$
  - Category B or A, if BMI $< 22$

- **Diet/exercise therapy**
  - Category B or A, if BMI $< 22$

**Step 1** (mono-category therapy)
- Category A, if BMI $\geq 25$
- Category A or B, if BMI 22 to $< 25$
- Category B or A, if BMI $< 22$

**Step 2** (combined therapy)
- Category A + category B (+ category D)

**Step 3** (insulin therapy)
- Category C (+ category A, B, and D)

* Pioglitazone is to be chosen whenever possible

**Blood Pressure**

- **Step 1**
  - Add a long-acting CCB

- **Step 2**
  - Add on a diuretic, $\beta$ blocker, and $\alpha$ blocker

**Lipid**

- **Step 1**
  - Maximal dose of the agents used in step 1

- **Step 2**
  - Add an anion-exchange resin and/or ezetimibe

* The omega-3 fatty acids are to be given if the goal for TG has not been achieved.
**List of participating investigators**

The J-DOIT3 Study Group are:

Asahikawa Medical University, Asahikawa, Hokkaido: Masakazu Haneda. Yoshida Hospital, Asahikawa, Hokkaido: Yasunori Iwashima. Hirosaki University Hospital, Hirosaki, Aomori: Toshihiro Suda, Naoki Tamasawa, and Makoto Daimon. Iwate Medical University Hospital, Morioka, Iwate: Jo Satoh, and Yasushi Ishigaki. Fukushima Medical University, Fukushima, Fukushima: Tsuyoshi Watanabe. Dokkyo Medical University Hospital, Mibu, Tochigi: Kikuo Kasai, and Yoshimasa Aso. Jichi Medical University, Shimotsuke, Tochigi: Shun Ishibashi. Saitama Medical University Hospital, Moroyama, Saitama: Shigehiro Katayama. Jichi Medical University Saitama Medical Center, Saitama, Saitama: San-e Ishikawa, and Masafumi Kakei. Saitama Red Cross Hospital, Saitama, Saitama: Kazuyuki Namai. Asahi General Hospital, Asahi, Chiba: Naotake Hashimoto, Yoshifumi Suzuki, and Shunichiro Onishi. Chiba University Medical School, Chiba, Chiba: Koutaro Yokote. Kameda Medical Center, Kamogawa, Chiba: Masafumi Matsuda, and Masahiro Masuzawa. Nihon University Itabashi Hospital, Itabashi, Tokyo: Yoichi Hayashi, Satoshi Saito, Norikazu Ogihara, and Hisamitsu Ishihara. The Jikei University School of Medicine, Minato, Tokyo: Naoko Tajima, and Kazunori Utsunomiya. Keio University School of Medicine, Shinjuku, Tokyo: Akira Shimada, and Hiroshi Itoh. Juntendo University
Graduate School of Medicine, Bunkyo, Tokyo: Ryuzo Kawamori, and Hirotaka Watada.

NTT Medical Center Tokyo, Shinagawa, Tokyo: Michio Hayashi. Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Minato, Tokyo: Yasumichi Mori. Mitsui Memorial Hospital, Chiyoda, Tokyo: Teruo Shiba, and Akihiro Isogawa. Tokyo Women’s Medical University Hospital, Shinjuku, Tokyo: Hiroshi Sakura.

Tokyo Medical University Hospital, Shinjuku, Tokyo: Masato Odawara. The University of Tokyo Hospital, Bunkyo, Tokyo: Kazuyuki Tobe, Kazuhisa Tsukamoto, and Toshimasa Yamauchi. Teikyo University School of Medicine Hospital, Itabashi, Tokyo: Tamio Teramoto. Tokyo Medical and Dental University, University Hospital of Medicine, Bunkyo, Tokyo: Yukio Hirata, Isao Uchimura, and Yoshihiro Ogawa. Toho University Medical Center, Ohmori Hospital, Ota, Tokyo: Gen Yoshino, and Takahisa Hirose. National Center for Global Health and Medicine Hospital, Shinjuku, Tokyo: Hiroshi Kajio. Saiseikai Central Hospital, Minato, Tokyo: Yoshihito Atsumi, and Akira Shimada. Tokyo Metropolitan Geriatric Hospital, Itabashi, Tokyo: Atsushi Araki. Hachioji Medical Center of Tokyo Medical University, Hachioji, Tokyo: Akio Ueki, and Atsushi Ohno. Showa General Hospital, Kodaira, Tokyo: Masafumi Kitaoka. Kitasato University Hospital, Sagamihara, Kanagawa: Yoshikuni Fujita, Tatsumi Moriya, Taiki Tojo, and Masayoshi Shichiri. Tokai University
School of Medicine, Isehara, Kanagawa: Daisuke Suzuki, and Masao Toyoda. Shonan
Kamakura General Hospital, Kamakura, Kanagawa: Kumiko Hamano, and Rieko Komi.
Yokohama City University Hospital, Yokohama, Kanagawa: Yasuo Terauchi. Yokohama
Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations,
Yokohama, Kanagawa: Nobuaki Kuzuya, and Masayo Yamada. Kanazawa University
Hospital, Kanazawa, Kanazawa: Toshinari Takamura. Yaizu City Hospital, Yaizu, Shizuoka:
Mitsuo Imura. Chukyo Hospital, Nagoya, Aichi: Hiroshi Tanaka, and Masayuki Hayashi.
Nagoya Medical Center, Nagoya, Aichi: Yasuhisa Kato. Fujita Health University Hospital,
Toyoake, Aichi: Mitsuyasu Itoh, and Atsushi Suzuki. Chubu Rosai Hospital, Nagoya, Aichi:
Nigishi Hotta, Jun Yosida, and Eitaro Nakashima. Mie University Hospital, Tsu, Mie:
Yasuhiro Sumida, and Yutaka Yano. National Hospital Organization Mie Chuou Medical
Center, Tsu, Mie: Tsuyoshi Tanaka. Ise Red Cross Hospital, Ise, Mie: Kazuya Murata. Shiga
University of Medical Science, Otsu, Shiga: Atsunori Kashiwagi, and Hiroshi Maegawa.
National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto: Shigeo Kono. Kyoto
University Hospital, Kyoto, Kyoto: Nobuya Inagaki. Osaka Police Hospital, Osaka, Osaka:
Keisuke Kosugi. National Cerebral and Cardiovascular Center, Suita, Osaka: Yasunao
Yoshimasa, and Ichiro Kishimoto. Osaka City General Hospital, Osaka, Osaka: Toshihiko